Bausch + Lomb Eyes Steady Growth with 5-7% Revenue Targets Through 2028

Bausch + Lomb (NYSE: BLCO) mapped out ambitious goals at its recent investor day, aiming to push revenue growth between 5% and 7% annually through 2028 on a constant currency basis. This sets the stage for a methodical ramp-up in top-line performance over the next several years.

Alongside its revenue objectives, the eye care leader is targeting an adjusted EBITDA margin of 23% by the end of that multi-year horizon. That speaks to operational discipline and efficiency gains, reflecting management's confidence in driving profitability as the business scales.

What caught attention is the hefty sales potential of Bausch + Lomb's pipeline products, with peak revenue estimates hovering around the $7 billion mark. These upcoming launches are clearly expected to be major contributors, injecting vitality into the company's future growth prospects.

Adjusted earnings per share are also projected to grow in the double digits from 2026 through 2028. This suggests management anticipates not just top-line expansion but also meaningful bottom-line leverage once pipeline initiatives mature and operational improvements take hold.

Reducing financial leverage is another focal point. Bausch + Lomb plans to lower its net leverage ratio to approximately 3.5 times by 2028, presumably to free up capital flexibility and shore up the balance sheet. This effort aligns with prudent debt management amid ongoing investments in product development.

The company reaffirmed its 2025 financial guidance during the presentation but kept specific numbers under wraps. That minor opacity leaves some questions about near-term performance, but the longer-term targets paint a pretty clear picture of strategic priorities.

Bausch + Lomb operates in a competitive segment of the eye health market. Its forward-looking estimates suggest it sees room to carve out growth despite ongoing challenges like pricing pressures or regulatory hurdles. The $7 billion pipeline figure hints at significant R&D investments bearing fruit.

Steady margins and double-digit EPS growth goals are encouraging signs that Bausch + Lomb is focused not just on selling more but on improving profitability and shareholder returns over time. The interplay between robust product launches and tighter financial controls will be something to watch in the coming years.